Following failed radiation therapy (RT) the best treatment of recurrent prostate cancer remains controversial due to the lack of long-term data. Researchers reviewed the survival and establish prognostic indicators for men who received salvage cryotherapy for biopsy-proven recurrent prostate cancer. […]
Every year around this time I say something about my personal hero, Rev. Dr.Martin Luther King Jr. This year is no exception. Of all the people I admire and respect in this world he is the one who has stayed consistent. Of course part of the reason for this is that his greatness has remained [...]
It has been announced that the application for the FDA approval of abiraterone with prednisone has been submitted by Centocor Ortho Biotech Inc. As I have discussed in prior posts, abiraterone is an extraordinarily promising investigational drug designed to treat metastatic advanced prostate cancer in men who have received prior chemotherapy containing a taxane. [...]
The investigational drug Abiraterone, designed for the treatment of men with advanced prostate cancer who have failed chemotherapy has not yet been approved by the FDA. Because of the extraordinarily positive results that were obtained on the phase III trials (which were stopped early because of these fantastic results) the pharmaceutical manufacturer of the drug [...]
Whether you are struggling with advanced prostate cancer, or a member of your family is, we all know how this journey can be very difficult. As we look forward to this New Year, 2011, we can be sure that there will be many difficult and down periods, but we should also remember there will also [...]
One of our biggest disputes around hormone deprivation (ADT) concerns the question of scheduling. Traditionally, ADT involved staying on the therapy drug forever. However, ADT causes significant side effects that negatively impacts both the quality of life as well as posing potential significant medical problems. Over the last five or so years there has been [...]
Researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Walter Reed Army Medical Center evaluated metastasis-free survival (MFS) and overall survival (OS) among men with a biochemical reoccurrence (PSA only) of prostate cancer after having received a radical prostatectomy but did not receive additional therapy until developing metastases […]
A PSA only recurrence (biochemical failure) post a primary treatment for prostate cancer is relatively common, approximately 30% of those treated! A biochemical failure is characterized a return of increasing PSA without any other evidence of cancer on a scan. Failure can happen immediately after primary treatment has been completed or many years after the [...]
There is a brief, but great YouTube video that very simply and clearly explains the current thinking about how and why prostate cancer becomes androgen independent (castrate resistant). View the video by clicking here Joel T Nowak, M.A., M.S.W.
To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for men with prostate cancer, researchers from the University of Illinois at Chicago and the Hind T. Hatoum & Company, Chicago, IL. evaluated a large contingent of men who had been diagnosed with prostate cancer from January 2003 to October [...]
